Sir,

Neonatal herpes simplex virus (HSV) infections are often life-threatening and difficult to diagnose. Most infections are treatable when they are detected early. Antiviral treatment should be strongly considered in infants with vesicular lesions at the earliest, even before a definitive culture or polymerase chain reaction results are available. Mortality following multi-organ disease in the absence of therapy is very high (80%), and most infants surviving central nervous system (CNS) or disseminated disease are neurologically impaired.

Here, we report a case of 10-day-old (3 kg) male baby who developed multiple grouped vesicles on erythematous base on anterior chest wall \[[Figure 1a](#F1){ref-type="fig"}\] on the 10^th^ day of life which was diagnosed as insect bite reaction by a general practitioner. On the 15^th^ day baby developed fever, lethargy, seizures and became unconscious and was brought to our institution. There was no history of genital lesions in mother. Baby was admitted in Neonatal Intensive Care Unit.

![(a) Case 1 - Multiple grouped vesicles on an erythematous base on the anterior chest wall. (b) Case 2 - Multiple, grouped and discrete vesicles on the chest and abdomen. (c) Case 2 - Tzanck test- multinucleated giant cells](IJD-61-122e-g001){#F1}

Another newborn baby (3.5 kg) was brought to us with the history of multiple, grouped and discrete vesicles in the axilla, chest, abdomen, \[Figures [1b](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\] and back of 2 days duration. There was a history of genital HSV lesions in the mother.

![Case 2 - Multiple, grouped and discrete vesicles in the axilla](IJD-61-122e-g002){#F2}

![Case 2 - Multiple, grouped and discrete vesicles on the abdomen](IJD-61-122e-g003){#F3}

In both cases, routine investigations such as complete blood picture, erythrocyte sedimentation rate, complete urine examination, chest X-ray and ultrasound abdomen were within normal limits. Specific investigations such as Tzanck smear \[[Figure 1c](#F1){ref-type="fig"}\] and Serology for HSV-2 antibodies (immunoglobulin M) were positive.

Based on clinical and laboratory evidence,first baby was diagnosed as neonatal HSV meningoencephalitis and the second baby was diagnosed as neonatal HSV infection (Skin, Eyes and Mouth \[SEM\] type).

In both the babies, we started intravenous (IV) acyclovir 20 mg/kg/dose thrice daily along with supportive therapy. We could not revive the first baby because of delayed diagnosis and treatment.

The second baby was given IV acyclovir for 14 days. All the lesions resolved and there was complete recovery without any sequelae.

Discussion {#sec1-1}
==========

Neonatal herpes can result from infection with either HSV-1 or -2, with the latter being associated with a poor prognosis.\[[@ref1]\] The most common cause of genital herpes in adults is HSV-2 in 85% of cases and in neonatal herpes it is seen in 70% of cases.\[[@ref2]\] Neonatal infection with HSV most often occurs during delivery. Infection can also occur in utero (congenital 5%) or following delivery (intrapartum 85%) or during the postpartum period (10%).\[[@ref3]\]

Neonatal HSV infection manifest as grouped vesicular lesions on an erythematous base localized to the SEM type, which is the earliest manifestation due to maternal transmission. The other findings are CNS involvement with or without SEM. The disseminated infection involving multiple organs such as the liver, lung, adrenal glands and/or brain can occur at a late stage.\[[@ref3]\]

A study conducted by Whitley RJ, Corey *et al*. and Kimberlin *et al*. found that the mortality rate in babies with SEM type of herpes is zero, and the neurological impairment is 38%. In neonatal herpes presenting with encephalitis, the mortality rate is 50%, and the neurological impairment is 67% whereas herpes presenting with disseminated type, the mortality rate is 85% and the neurological impairment is 50%.\[[@ref4]\] This gives further evidence that neonatal herpes if not diagnosed and treated early will lead to further complications as we have reported in our first case. SEM disease presents at approximately at 10--11 days after birth.\[[@ref5]\] Disease limited to the SEM is manifested by discrete vesicles and keratoconjunctivitis. Unless there is an index of suspicion, it is difficult to diagnose herpetic infection in spite of cutaneous vesicular lesions. Though there is no mortality associated with SEM type, 30--40% develops neurological impairment if they do not receive antiviral therapy. The significant neurological findings include spastic quadriplegia, microcephaly and blindness that become apparent in the following 6--12 months. Infants may appear healthy, and some many have a subclinical infection of the CNS. Moreover, 75% of babies with SEM infection progress to either CNS involvement or disseminated disease in the absence of antiviral therapy.\[[@ref4]\] This is probably due to widespread viremia leading to the involvement of the brain, liver, or lungs. Hence, all infants with SEM disease should be treated aggressively and followed-up carefully up to 6--12 months.

Depending on disease classification and duration of treatment with acyclovir ranging from 10 to 21 days improves morbidity and mortality. Acyclovir is used because of its safety and convenient dosing regimen.\[[@ref5]\]

Conclusions {#sec1-2}
===========

HSV infections in the neonate have the potential to cause significant morbidity and mortality. Recognition of herpes simplex in neonates is difficult unless there is a high index of suspicion evaluating vesicular lesions. Early diagnosis and treatment decrease the morbidity and mortality.
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